Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.

Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer. - Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006057

Enrollment

Registered

2011-08-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advance or recurrent colorectal cancer.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patient With estimative lesion and Histological confirmation of colorectal cancer. (2) Patients with unresectable colorectal cancer who had received no previous therapy. (3) Patient who is scheduled to be administered the combination of XELOX + Bevacizumab. (4) Patient who is 20 years old or more. (5) Eastern Cooperative Oncology Group (ECOG) performance status (PS) : 0 - 2. (6) Appropriate for the study at the physician's assessment. (7) Written informed consent.

Exclusion criteria

Exclusion criteria: (1)Patient who fall under the a package insert "contraindication" or "Contraindicaton in combination" with Bevacizumab , Oxaliplatin and Capecitabine. (2) Not appropriate for the study at the physician's assessment

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Response rate Response rate at the fourth course Time-to-treatment failure Overall survival Resection rate in subjects with liver metastasis R0 resection rate in subjects with liver metastasis Safety Assessment of Quality of life (Dermatology Life Quality Index)	—

Countries

Japan

Contacts

Public ContactMasayuki Hisada

Tokyo Medical University The third department of surgery

m-hisada@tokyo-med.ac.jp03-3342-6111

Outcome results